Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 2/2010

01-02-2010 | Original Article

A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer

Authors: Glenn D. Flux, Masud Haq, Sarah J. Chittenden, Susan Buckley, Cecilia Hindorf, Kate Newbold, Clive L. Harmer

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2010

Login to get access

Abstract

Purpose

The aim of this study was to determine the range of absorbed doses delivered to thyroid remnants, blood, and red marrow from fixed administrations of radioiodine and to ascertain whether the success of ablation is more dependent on these absorbed doses than on the administered activity.

Methods

Twenty-three patients received 3,000 MBq radioiodine following near-total thyroidectomy. The maximum absorbed dose to remnants was calculated from subsequent single photon emission tomography scans. Absorbed doses delivered to blood and red marrow were calculated from blood samples and from whole-body retention measurements. The protein bound iodine (PBI) was also calculated.

Results

Maximum absorbed doses to thyroid remnants ranged from 7 to 570 Gy. Eighteen of the 23 patients had a successful ablation. A significant difference was seen between the absorbed doses delivered to thyroid remnants, blood, and red marrow for those patients that had a successful ablation compared to those with a failed ablation (p = 0.030, p = 0.043 and p = 0.048, respectively). The difference between the PBI values acquired at day 1 and day 6 were also indicative of response (p = 0.074).

Conclusions

A successful ablation is strongly dependent on the absorbed dose to the thyroid remnant. Dosimetry-based personalized treatment can prevent both sub-optimal administrations, which entails further radioiodine therapy, and excessive administration of radioactivity, which increases the potential for radiation toxicity.
Literature
1.
Haq M, Harmer C. Non-surgical management of thyroid cancer. In: Mazzaferri EL, Harmer C, Mallick U, Kendall-Taylor P, editors. Practical management of thyroid cancer. London: Springer-Verlag; 2006. p. 171–91.CrossRef
2.
Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154(6):787–803.CrossRefPubMed
3.
Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn JA. Review: I-131 activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metab. 2007;92(1):28–38.CrossRefPubMed
4.
Mallick U, Harmer C, Hackshaw A. The HiLo trial: a multicentre randomised trial of high- versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer. Clin Oncol. 2008;20(5):325–6.CrossRef
5.
Benua RS, Cicole NR, Sonenburg N, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid carcinoma. Am J Roentgenol Radium Ther Nucl Med. 1962;87:171–82.PubMed
6.
Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, Gulec SA. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med. 2003;44(3):451–6.PubMed
7.
O'Connell MEA, Flower MA, Hinton PJ, Harmer CL, McCready VR. Radiation-dose assessment in radioiodine therapy—dose-response relationships in differentiated thyroid-carcinoma using quantitative scanning and PET. Radiother Oncol. 1993;28(1):16–26.CrossRefPubMed
8.
Maxon HR, Thomas SR, Samaratunga RC. Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Thyroid. 1997;7(2):183–7.CrossRefPubMed
9.
Koral KF, Adler RS, Carey JE, Beierwaltes WH. I-131 treatment of thyroid-cancer—absorbed dose calculated from post-therapy scans. J Nucl Med. 1986;27(7):1207–11.PubMed
10.
Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sc. 1978;25:638–43.CrossRef
11.
Chittenden S, Pratt B, Pomeroy K, Black P, Long C, Smith N, et al. Optimization of equipment and methodology for whole-body activity retention measurements in children undergoing targeted radionuclide therapy. Cancer Biother Radiopharm. 2007;22(2):247–53.
12.
Loevinger R, Budinger T, Watson E. MIRD primer for absorbed dose calculations. New York: Society of Nuclear Medicine; 1988.
13.
Hanscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006;47(4):648–54.PubMed
14.
Cristy M, Eckerman K. Specific absorbed fractions of energy at various ages from internal photon sources. ORNL/TM-8381 V1–V7. Oak Ridge: Oak Ridge National Laboratory; 1987.
15.
Flux GD, Guy MJ, Beddows R, Pryor M, Flower MA. Estimation and implications of random errors in whole-body dosimetry for targeted radionuclide therapy. Phys Med Biol. 2002;47(17):3211–23.CrossRefPubMed
16.
Lassmann M, Haenscheid H, Chiesa C, Hindorf C, Flux G, Luster M. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imag. 2008;35(7):1405–12.CrossRef
17.
Zieve L, Vogel WC, Schultz AL. Determination of protein-bound radioiodine with an ion-exchange resin. J Lab Clin Med. 1956;47:663–8.PubMed
18.
Hammersley PAG, Al Saadi A, Chittenden S, Flux GD, McCready VR, Harmer CL. Value of protein-bound radioactive iodine measurements in the management of differentiated thyroid cancer treated with I-131. Br J Radiol. 2001;74(881):429–33.PubMed
19.
Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJG, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941–59.CrossRefPubMed
20.
Perros P, Clarke SEM, Franklyn J et al (2007) British Thyroid Association and Royal College of Physicians. Guidelines for the management of thyroid cancer, 2nd edn.
21.
Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. The American Thyroid Association Guidelines Taskforce. Thyroid. 2006;16(2):109–41.CrossRefPubMed
22.
Hyer S, Kong A, Pratt B, Harmer C. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin Oncol. 2007;19(1):83–6.CrossRef
23.
Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Brit J Cancer. 2003;89(9):1638–44.CrossRefPubMed
24.
Dewaraja YK, Wilderman SJ, Ljungberg M, Koral KF, Zasadny K, Kaminiski MS. Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation. J Nucl Med. 2005;46(5):840–9.PubMed
25.
Buckley SE, Saran FH, Gaze MN, Chittenden SC, Partridge M, Lancaster D, et al. Dosimetry for fractionated I131 mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results. Cancer Biother Radiopharm. 2007;22(1):105–12.CrossRefPubMed
26.
Hermanska J, Karny M, Zimak J, Jirsa L, Samal M, Vlcek P. Improved prediction of therapeutic absorbed doses of radioiodine in the treatment of thyroid carcinoma. J Nucl Med. 2001;42(7):1084–90.PubMed
27.
Sgouros G, Kolbert KS, Sheikh A, Pentlow, Mun EF, Barth A, et al. Patient-specific dosimetry for I-131 thyroid cancer therapy using I-124 PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med. 2004;45(8):1366–72.PubMed
28.
Stabin MG. The case for patient-specific dosimetry in radionuclide therapy. Cancer Biother Radiopharm. 2008;23(3):273–84.CrossRefPubMed
29.
Lassmann M, Luster M, Hanscheid H, Reiners C. Impact of I-131 diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med. 2004;45(4):619–25.PubMed
30.
Sisson JC, Avram AM, Lawson SA, Gauger PG, Doherty GM. The so-called stunning of thyroid tissue. J Nucl Med. 2006;47(9):1406–12.PubMed
Metadata
Title
A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer
Authors
Glenn D. Flux
Masud Haq
Sarah J. Chittenden
Susan Buckley
Cecilia Hindorf
Kate Newbold
Clive L. Harmer
Publication date
01-02-2010
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2010
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-009-1261-3

Other articles of this Issue 2/2010

European Journal of Nuclear Medicine and Molecular Imaging 2/2010 Go to the issue

Focus on

Molecular imaging in cognitive impairment: the relevance of cognitive reserve, importance of multisite longitudinal trials and challenges of standardised analysis

Letter to the Editor

PET/CT for the assessment and quantification of 90Y biodistribution after selective internal radiotherapy (SIRT) of liver metastases

Original Article

Radiobiological effects of hypoxia-dependent uptake of 64Cu-ATSM: enhanced DNA damage and cytotoxicity in hypoxic cells

Review Article

Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies

Original Article

Potential impact of 68Ga-DOTATOC PET/CT on stereotactic radiotherapy planning of meningiomas

Society communications

Certificate of Fellowship of the European Board of Nuclear Medicine 2010 Information